Metals One PLC (AIM:MET1, FRA:HT7, OTCQB:MTOPF), the critical and precious metals developer, has expanded its agreement with DISA Technologies to evaluate and potentially treat abandoned uranium mine waste dumps at its Uravan Belt project in Colorado.
The deal covers eight separate waste dumps across the property, a 490-hectare site comprising 59 unpatented mining claims near the historic Buckhorn Mine.
DISA will deploy its patented high-pressure slurry ablation (HPSA) technology, a modular mobile process that extracts uranium and other critical minerals from surface waste material while removing around 90% of uranium and radium-226 content, delivering significant environmental benefits.
Crucially for Metals One, the agreement requires no capital or operating expenditure from the company.
DISA will act as operator and cover all costs of permitting, evaluation, treatment and ongoing remediation.
In return, Metals One will receive a gross revenue share on saleable concentrates recovered, on a sliding scale from 2.5% to 4.0% depending on metals pricing conditions.
The arrangement expands on an existing relationship with DISA covering Metals One's 75%-owned Radium Mountain and Wedding Bell claims, also in Colorado.
The Uravan project sits within the Uravan Mineral Belt, a district that produced more than 60 million pounds of uranium and 330 million pounds of vanadium during the 20th century.
Rock chip sample assays announced in September 2025 returned grades of up to 41,768 parts per million uranium, equivalent to 4.17%, from historic waste material.
DISA became the first company to receive a service provider's licence from the US Nuclear Regulatory Commission in September 2025, providing a regulatory pathway for the remediation of abandoned uranium mine waste.
The agreement aligns with a recent US Department of the Interior secretarial order aimed at unlocking critical minerals from legacy mine waste.
Managing director Daniel Maling said DISA had made strong early progress on the Radium Mountain and Wedding Bell claims, with gamma walkover data expected by the end of this month and assay results by the end of the third quarter.
Next steps at Uravan include a characterisation programme and permitting ahead of any treatment and recovery activity.